Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its MetaHealthU mobile application platform will focus on determining the cause and finding a possible cure for hallucinogen-persisting perception disorder (HPPD). Ehave has pioneered HPPD research efforts by launching a series of studies through its partnership with the University of Melbourne to gather data and biomarkers to target the condition. HPPD, (HPPD) or “flashbacks” is the only recognized long-term complication of hallucinogen use. It can cause a person to keep reliving the visual element of an experience caused by hallucinogenic drugs. As psychedelics become more widely accepted, the data and biomarkers from Ehave’s MetaHealthU will enhance research into HPPD, which will assist medical and mental health professionals to diagnose if an individual is genetically predisposed to suffer from the condition.
Some key points about EHVVF –
– Therapeutics to Address Brain Disorders, Diseases & Mental Health Issues.
– Expanding Mobile Psychedelic Service by Providing Licensed Psychotherapists and Registered Nurses.
– Agreement with Heally Platform for Electronic Medical Record Telehealth.
– Licensing Partner Vastmindz Seen by Millions of Viewers on Unicorn Hunter Program.
– In-Home Ketamine Therapy Launched in San Francisco & Sacramento.
– 100% Acquisition of Rejuv IV Which Provides Mobile IV Therapy
Ehave, Inc. (OTC: EHVVF) is a leading healthcare services and technology company, focused on progressing psychedelics-to-Therapeutics by engineering novel compounds and new treatment protocols for treating brain health. Together with its network of scientists and mental health professionals, EHVVF is on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues, leveraging clinical data to help us achieve optimal patient outcomes. EHVVF operations span across the entire USA, Canada, Jamaica, and Australia.
EHVVF Continues Expansion of KetaDASH Mobile Psychedelic Service by Providing Licensed Psychotherapists and Registered Nurses –
– Agreement with Heally adds doctors, licensed psychotherapists and registered nurses to the KetaDASH platform.
– With the opening of KetaDASH, EHVVF builds momentum for the psychedelic renaissance in the mental health field.
– Both the KetaDASH patient and nurse connect to a psychotherapist via Heally’s telehealth portal for each treatment session.
On March 3rd EHVVF announced it will partner with Heally, the all-in-one platform and electronic medical record (EMR)/telehealth solution for alternative medicine providers, to provide Licensed Psychotherapists and Registered Nurses to EHVVF KetaDASH patients. This mobile solution departs from in-person intravenous treatment, as well as unsupervised telehealth models.
EHVVF KetaDASH service provides patients with an in-home setting that offers a space for healing, growth and transformation through psychedelic therapies.
EHVVF Licensing Partner Vastmindz Seen by Millions of Viewers on Unicorn Hunter Program –
On February 24th EHVVF announced that its AI technology licensing partner, Vastmindz, was recently featured on Unicorn Hunters, “the most iconic business series of recent times,” according to Forbes magazine. The episode featuring Vastmindz began streaming on UnicornHunters.com, Binge Networks, LinkedIn Broadcast, Facebook Video, YouTube, and Vimeo.
Vastmindz aims to transform regular consumer technology devices into comprehensive health screening tools using artificial intelligence. in 2022, EHVVF plans to monetize the AI technology it licensed from Vastmindz to expand the EHVVF Dashboard and MetaHealthU offering.
EHVVF Launches KetaDASH, In-Home Ketamine Therapy in San Francisco And Sacramento Markets –
On February 15th EHVVF announced that its wholly-owned subsidiary, KetaDASH, commenced clinical operations, would be offering in-home ketamine therapy to patients suffering from treatment-resistant mental health issues. Initially, the treatment will be offered in the San Francisco Bay Area and Greater Sacramento Area with plans to expand to other markets in the coming months.
EHVVF KetaDASH treatments will be conducted by a team of experienced nurses who will come to patients’ homes, offices, or mobile location after initial telemedicine screening and provide a complete ketamine experience, with a focus on set and setting, with packages that include telemedicine integration with psychotherapists.
EHVVF Expands KetaDASH Brand and Begins Producing Revenue with The Purchase of California Based Rejuv IV –
On February 9th EHVVF reaffirmed its commitment to launching its KetaDASH brand by completing the purchase of 100% of Rejuv IV which provides mobile IV therapy in the San Francisco Bay Area, 7 days a week with flexible scheduling. Rejuv IV provides Ketamine treatments, as well as IV infusions with fluids, essential vitamins, minerals, and electrolytes to enhance the health and wellness of its patients. With the acquisition, Rejuv IV became KetaDASH, a wholly-owned subsidiary of EHVVF.
For more information on Ehave, Inc. (EHVVF) visit: http://www.ehave.com
DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way to buying or selling stocks.